Business Context and Reporting Period
This Form 8-K Current Report is filed by Aytu BioScience, Inc. (trading as AYTU) for the period ending June 30, 2020, with the report date of July 2, 2020. The filing details material definitive agreements regarding executive compensation adjustments and the issuance of unregistered equity securities.
Key Financial Metrics and Agreements
The filing does not provide standard financial performance metrics such as revenue, net income, cash flow, or debt levels. Instead, it discloses specific financial obligations and equity transactions:
- Restricted Stock Exchange: The Company entered into agreements to cancel 859,725 shares of previously authorized but unissued restricted stock (granted in November 2019) and pay cash in exchange. The total cash consideration is approximately $843,576, calculated at the November 2019 closing price of $0.98 per share.
- Executive Compensation Increases:
- CEO (Joshua Disbrow): Base salary increased to $500,000 (effective June 1, 2020) and scheduled to rise to $590,000 (effective Jan 1, 2021). Annual bonus target reduced from 100% to 60% of base salary. Granted 100,000 options and 450,000 restricted shares.
- CFO (David Green): Base salary increased to $375,000 (effective June 1, 2020) and scheduled to rise to $400,000 (effective Jan 1, 2021). Granted 100,000 options and 250,000 restricted shares.
- Warrant Issuance: Issued warrants to H.C. Wainwright & Co., LLC for 923,000 shares at an exercise price of $1.7625 per share. The warrants are immediately exercisable with a one-year term.
Material Changes Versus Prior Period
The filing highlights a strategic shift in compensation structure driven by the Company's "current cash position" and a desire to avoid dilution:
- Equity to Cash Conversion: Unlike the prior authorization of restricted stock in November 2019, the Company elected to settle these obligations in cash to mitigate dilutive effects on existing stockholders.
- Compensation Structure: Significant increases in base salaries for the CEO and CFO were implemented, accompanied by new equity grants (options and restricted stock) effective July 1, 2020, replacing the previous unissued grant.
Outlook, Risks, and Management Commentary
Management Commentary: The Compensation Committee determined that converting the November 2019 equity grant to cash was in the best interest of the Company and stockholders due to liquidity constraints and principles of fairness. The new employment amendments were designed to reward executive performance.
Risks and Contingencies:
- Liquidity: The decision to pay cash for the stock exchange implies cash flow considerations. Payments to board members will be made in arrears via board retainers, while payments to the CEO and CFO are split between immediate and future dates (June 30, 2020, and July 1, 2021).
- Change in Control: The RSCE Agreement stipulates that if a "Change in Control" or "Separation Event" occurs, the remaining Restricted Stock Exchange Amount must be paid within 30 days.
Investor Verification Checklist
- Verify the Company's current cash balance and liquidity status to assess the ability to fund the ~$843,576 cash settlement and increased executive salaries.
- Review the impact of the 923,000 warrants issued to H.C. Wainwright on potential future dilution if exercised at $1.7625.
- Confirm the total number of new restricted shares and options granted to the CEO and CFO (700,000 restricted shares and 200,000 options combined) and their vesting schedules.
- Monitor the payment schedule for the RSCE Agreement, specifically the July 1, 2021, installment for the CEO and CFO.